- Home
- COLL
as of 01-07-2026 2:09pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 1.5B | IPO Year: | 2015 |
| Target Price: | $47.50 | AVG Volume (30 days): | 496.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.63 | EPS Growth: | -24.84 |
| 52 Week Low/High: | $23.23 - $50.79 | Next Earning Date: | 02-26-2026 |
| Revenue: | $757,067,000 | Revenue Growth: | 26.34% |
| Revenue Growth (this year): | 26.35% | Revenue Growth (next year): | 3.67% |
AI-Powered COLL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
EVP & Chief Commercial Officer
Avg Cost/Share
$48.28
Shares
17,600
Total Value
$847,855.20
Owned After
110,088
Director
Avg Cost/Share
$47.03
Shares
3,650
Total Value
$171,673.37
Owned After
52,629
SEC Form 4
Director
Avg Cost/Share
$47.21
Shares
34,853
Total Value
$1,645,535.60
Owned After
64,634
SEC Form 4
EVP & Chief Financial Officer
Avg Cost/Share
$40.83
Shares
30,000
Total Value
$1,215,753.34
Owned After
131,525
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Dec 8, 2025 | Sell | $48.28 | 17,600 | $847,855.20 | 110,088 | |
| Balice-Gordon Rita J. | COLL | Director | Dec 5, 2025 | Sell | $47.03 | 3,650 | $171,673.37 | 52,629 | |
| Fallon John A. | COLL | Director | Nov 12, 2025 | Sell | $47.21 | 34,853 | $1,645,535.60 | 64,634 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Nov 6, 2025 | Sell | $40.83 | 30,000 | $1,215,753.34 | 131,525 |
Compare COLL vs Leading Stocks
See how COLL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.